HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Equity Capital Markets

<ul>
<li>FS adopts a unique light-asset business model of "R&amp;D design + outsourcing production + direct sales platform", which leads to higher profit margin than traditional channel sales vendors.</li>
<li>FS once failed in A-Share IPO and received penalty in 2025. Internal control defects are the "Achilles heel", which makes us worry whether FS has the problem of "inflating revenue". </li>
<li>Although FS has positive performance growth, the uncertainty of Sino-US relations and exchange rate risks may put pressure on profitability. Valuation of FS could be lower than peers. </li>
</ul>


FS adopts a unique light-asset business model of "R&amp;D design + outsourcing production + direct sales platform", which leads to higher profit margin than traditional channel sales vendors.
FS once failed in A-Share IPO and received penalty in 2025. Internal control defects are the "Achilles heel", which makes us worry whether FS has the problem of "inflating revenue". 
Although FS has positive performance growth, the uncertainty of Sino-US relations and exchange rate risks may put pressure on profitability. Valuation of FS could be lower than peers. 


Pre-IPO FS.COM - The Concerns Behind the Business Model and the Outlook